S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

$43.05
+0.05 (+0.12%)
(As of 03/28/2024 ET)
Today's Range
$42.38
$43.55
50-Day Range
$42.66
$50.04
52-Week Range
$27.99
$50.99
Volume
364,266 shs
Average Volume
373,975 shs
Market Capitalization
$3.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.67

Xenon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.3% Upside
$58.67 Price Target
Short Interest
Healthy
3.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$931,940 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.33 out of 5 stars

Medical Sector

350th out of 938 stocks

Pharmaceutical Preparations Industry

162nd out of 432 stocks

XENE stock logo

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Stock Price History

XENE Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Xenon Pharmaceuticals Inc
XENE Apr 2024 47.500 put
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XENE
Employees
251
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.67
High Stock Price Target
$63.00
Low Stock Price Target
$51.00
Potential Upside/Downside
+36.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-182,390,000.00
Pretax Margin
-123,568.95%

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$14.18 per share

Miscellaneous

Free Float
71,336,000
Market Cap
$3.25 billion
Optionable
Optionable
Beta
1.17
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 48)
    CPA, M.B.A., President, CEO & Director
    Comp: $973.76k
  • Ms. Sherry Aulin (Age 40)
    Chief Financial Officer
    Comp: $3.03M
  • Ms. Andrea DiFabio J.D. (Age 56)
    Chief Legal Officer & Corporate Secretary
    Comp: $200.51k
  • Dr. Christopher E. Von Seggern M.B.A. (Age 45)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
    Comp: $618.07k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 53)
    Chief Medical Officer
    Comp: $684.22k
  • Ms. Shelley McCloskey B.A. (Age 64)
    Executive Vice President of Human Resources
  • Dr. Robin P. Sherrington Ph.D. (Age 63)
    Executive Vice President of Strategy & Innovation
    Comp: $351.67k
  • Dr. James R. Empfield Ph.D. (Age 63)
    Executive Vice President of Drug Discovery
    Comp: $323.43k
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Executive Vice President of R&D Operations

XENE Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price target for 2024?

9 brokers have issued 12-month target prices for Xenon Pharmaceuticals' shares. Their XENE share price targets range from $51.00 to $63.00. On average, they anticipate the company's share price to reach $58.67 in the next twelve months. This suggests a possible upside of 36.3% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2024?

Xenon Pharmaceuticals' stock was trading at $46.06 on January 1st, 2024. Since then, XENE stock has decreased by 6.5% and is now trading at $43.05.
View the best growth stocks for 2024 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.12. Xenon Pharmaceuticals's revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.57) earnings per share.

What ETFs hold Xenon Pharmaceuticals' stock?
What other stocks do shareholders of Xenon Pharmaceuticals own?
Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (8.66%), Wellington Management Group LLP (5.52%), Capital World Investors (4.10%), Capital International Investors (3.75%), Commodore Capital LP (3.31%) and Braidwell LP (2.52%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin, Simon N Pimstone and Steven Gannon.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XENE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners